lung cancer
Conditions
Interventions
Experimental group:helical tomotherapy
The control group:three-dimensional conformal radiotherapy
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients should be diagnosed as NSCLC histologically or cytologically; 2. CT/PET-CT staging should be stage III (IIIA T4N0-1M0, T3N1M0, T1-3N2M0; IIIB T4N2M0, TxN3M0); 3. Age >=18 years old; 4. KPS scores>=60,the weight loss in last 6 months4.0*10^9/L, absolute neutrophil count>1.5*10^9/L,hemoglobin>110g/L,platelet count>100*10^9/L; liver function: bilirubin of blood cholesterol 1L or FEV1>40% predicted value, DLCO>30%predicted value; 6. The patient has chest CT in recent 4 weeks, the measurable focus, and cranial CT or MRI or FDG-PET before being admitted. CT scan is needed (unless there is contraindication, venous enhancement will be better), including bilateral lung, mediastinum, liver, and adrenal gland; 7. life expectancy >=12 weeks; 8. The size of primary tumor must be measured by CT; 9. no other cancer; 10. patients can understand the situation of the study and has signed informed consent.
Exclusion criteria
Exclusion criteria: 1) obvious neurologic or psychiatric history; such as Alzheimerdisease, which may affect comprehensive ability; 2) Being diagnosed as small cell lung cancer histologically or cytologically; 3) KPS score <50 or PS score is 3-4; 4) Pregnant and lactant women or women with positive pregnancy test; 5) severe comorbidity and complication; 6) Patients who have poor adherence; 7) The patient is confirmed to be regional or distant metastasis with PET exams or postoperative staging; or the patient has primary cancer or precancerous lesion (excluding non-melanomas malignant skin cancer or carcinoma in situ) in past 3 years; 8) Patients who had received radiotherapy because of tumors such as lung cancer, breast cancer and lymphoma will have higher risk of SBRT, because their previous target volumes may coincide with SBRT; 9) Pure bronchioalveolar carcinoma; 10) Active systemic infection or lung, pericardium infection; 11) The patient who has history chemotherapy or has pulmonary resection or pneumonectomy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival rate;Local control rate; | — |
Countries
China
Contacts
Public ContactHe Jian
Outcome results
None listed